英文名称 | Fenofibric-d6 Acid
|
CAS编号 | 1092484-69-9 |
产品描述 | 非诺比利酸-d6(FNF酸-d6)是氘标记的非诺比利酸。非诺贝特的活性代谢物非诺贝特酸是PPAR活化剂,PPARα、PPARγ和PPARδ的EC50分别为22.4µM、1.47µM和1.06µM;非诺比利酸也抑制COX-2酶活性,IC50为48 nM。 |
精确质量 | 324.10400 |
PSA | 63.60000 |
LogP | 3.81300 |
体外研究 |
氢、碳和其他元素的稳定重同位素已被纳入药物分子,主要作为药物开发过程中定量的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而受到关注。
|
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[2]. Dietz M, et al. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem. 2012 Jun;7(6):1101-11.
[3]. Prasad GS, et al. Anti-inflammatory activity of anti-hyperlipidemic drug, fenofibrate, and its phase-I metabolite fenofibric acid: in silico, in vitro, and in vivo studies. Inflammopharmacology. 2017 Dec 13.
[4]. Neumeier M, et al. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem Biophys Res Commun. 2006 Nov 24;350(3):731-5. Epub 2006 Sep 27.
[5]. Miranda S, et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. J Cell Physiol. 2012 Jun;227(6):2352-62.